Breaking News

ANI, Sterling Enter Generic Drug Pact

By Kristin Brooks | January 6, 2014

ANI to provide commercial manufacturing services

ANI Pharmaceuticals, Inc. has entered into a fee-for-service development agreement with Sterling Pharmaceutical Services for an undisclosed generic drug product. The product will be developed by Sterling and transferred to ANI's facilities for commercial manufacture and marketing. According to IMS Health, the annual market for the product is valued at $60 million.
Arthur S. Przybyl, ANI's president and chief executive officer, said, "We are pleased to have entered into this initial collaboration with such a high quality partner as Sterling. We hope to place additional projects with Sterling in the future."
Robert Flynn, president of Sterling, said, "We are excited about the new relationship formed with ANI. This will allow both parties to utilize their expertise for the benefit of our respective companies and the consumer."

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks